EMD Millipore, Plasticell in Licensing Pact

EMD Millipore, the Life Science division of Merck KGaA, has entered an agreement with Plasticell to distribute a single-application osteogenic medium discovered using the CombiCult screening system.
 
The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations, according to the company. EMD Millipore has secured a license to distribute the medium globally for research purposes and Plasticell retains full rights for therapeutic applications.
 
The optimized osteogenic medium was developed using CombiCult to perform a rapid screen of 3,375 combinations of fully defined cell culture media. “The formulation of this medium in under three months from start to finish is a clear demonstration of the capability of the CombiCult technology to deliver market-leading products in record time,” said Dr. Jey Jeyakumar, the principal scientist who performed the factor screen and optimized the media formulation.